Loading clinical trials...

Phase I, Open Label, Single Center Safety Study of [F-18]FLT | Clinical Trials | Clareo Health

COMPLETEDPHASE1

Phase I, Open Label, Single Center Safety Study of [F-18]FLT

A Phase I, Open Label, Single Center Safety Study of [F-18]FLT

NCT00553748•Siemens Molecular Imaging

Summary

This is a ten subject, phase 1 study. The purpose of the Phase 1 study is to demonstrate drug safety in a target group of subjects with high grade brain cancer. This population represents a potential clinical population that may benefit from this PET imaging tracer. The study will also begin collection of baseline imaging data and allow us to gain information to improve design and conduct of future trials.

Detailed Description

This is a ten subject, phase 1 study. The purpose of the study is to demonstrate drug safety in a group with high grade brain tumors and to evaluate cell proliferation with F-18 FLT. FLT is known to clear out of normal brain and detect brain tumor. This population represents a potential clinical population that may benefit from this PET imaging tracer. This information will help improve the design and conduct of future F-18 FLT clinical trials.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Subject may be male or female and of any race / ethnicity;
•At the time of study drug dosing, the subject has reached his or her 18th birthday;
•Subject has histologic diagnosis of one of the following malignancies - glioblastoma gliosarcoma, anaplastic mixed/anaplastic oligodendroglioma or (anaplastic) astrocytoma with lesion visible on CT or MR and minimum histological grade of III/IV;
•Subject with suspect radiation necrosis that are planned for re-section;
•Subject or subject's legally acceptable representative provides informed consent;
•Subject is capable of complying with study procedures and able to lie still in the PET scanner;
•Subject is capable of communicating with study personnel;
•Subject has adequate liver and kidney function

Exclusion Criteria

•Subject is pregnant or nursing;
•Subject is anemic (as defined as a hemoglobin level \<10);
•Subject has not received chemotherapy or radiation therapy within the two weeks prior to imaging.
•Subject has as reflected by a serum liver enzymes outside the normal laboratory reference range;
•Subject has a history of chronic liver disease, which may compromise liver function;
•Subject has kidney disease as reflected by a serum creatinine outside the normal laboratory reference range;
•Subject has prior history of stroke or other condition of the head or neck that, in the investigator's opinion, might affect circulation to the brain or image interpretation (examples include, but are not limited to, previous stroke with cystic softening and cerebral deformity, or arteriovenous malformation);
•Subject has a history of significant cerebrovascular disease;
•Subject has any other condition or personal circumstance that, in the judgment of the investigator, might interfere with the collection of complete good quality data
•Subject has previously received \[F-18\]FLT at any time, or any other investigational product within the past two weeks.

Locations (1)

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, United States

Key Dates

Start Date

November 1, 2007

Primary Completion Date

May 1, 2008

Completion Date

May 1, 2008

Last Updated

July 3, 2008

Enrollment

ACTUAL participants

Conditions

Brain Cancer

Interventions

F-18 FLT

DRUG

Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker

NCT02691923

Brain Cancer

View study

RECRUITINGPHASE1/PHASE2

Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM

NCT03213002

Glioblastoma Multiforme (GBM)Glioblastoma+7 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 3, 2008Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Phase I, Open Label, Single Center Safety Study of [F-18]FLT

Inclusion Criteria

Exclusion Criteria

Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker

Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM

Record Voxel Rate Nonlinear Optical Microscope to Unravel Brain Connectome and Signaling

Wearable Devices and Biomarkers Project (Healthiomics)

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

A Study to Evaluate the Safety and Efficacy of Intracranial Venous Blood Sampling for Liquid Biopsy in the Diagnosis of Brain Cancers